CU Cancer Center Lung Cancer Treatment to be Commercialized by Syndax Pharmaceutical
May 9, 2013 · Comments Off
Licensing agreement allows development of a novel combination therapeutic for non-small-cell lung carcinoma, a type of lung cancer difficult to treat with conventional chemotherapy.
The current state of lung cancer treatment
December 11, 2012 · Comments Off
A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.
Drug combination nearly doubles survival for subset of advanced non-small cell lung cancer patients
April 26, 2012 · Comments Off
THREE KEY POINTS: Results of 30-center phase II clinical trial show that combination of erlotinib...
First and only drug for ALK-positive lung cancer approved today
August 26, 2011 · Comments Off
Aurora, CO (8.26.2011) – In a major triumph for personalized medicine, today the FDA approved...
Study: Iloprost improves lung damage in nonsmokers
April 26, 2011 · Comments Off
Researchers at the University of Colorado Cancer Center have shown that use of an oral...
New combo lung cancer therapy improves survival over single-line treatment
December 14, 2010 · Comments Off
University of Colorado-developed treatment effective in Phase 2 Trials in a biomarker-selected group of patients...
Setting the Gold Standard
March 15, 2009 · Comments Off
When Dr. Marileila Varella-Garcia got an email in 2004, she opened the attached spreadsheet and...
Celebrating a 20-year collaboration with CSU’s Animal Cancer Center
December 1, 2008 · Comments Off
In June, the University of Colorado and Colorado State University celebrated 20-plus years of collaboration in cancer research. Colorado State is one of the three academic institutions that make up CU Cancer Center, alongside University of Colorado Denver and University of Colorado Boulder.
Bitter melon juice prevents pancreatic cancer in mouse models
December 1, 2008
NTRK1: a new oncogene and target in lung cancer
December 1, 2008
“Dramatic” Early Phase 1 Results for AG-120 in IDH1 Mutated AML
November 24, 2014 · No comments
University of Colorado Hospital Now Offering Lung Cancer Screening
November 13, 2014 · No comments
CU Cancer Center brings specialty care to Colorado
November 12, 2014 · No comments
ALK amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Congratulations to Dr. Dan Pollyea for his outstanding presentation at the European Organisation for Research and... fb.me/3isnI2xHi